This financing will support proof-of-concept studies with Kereos' tumor-targeted magnetic resonance imaging (MRI) agent, which supports early cancer diagnosis by allowing physicians to see tumors as small as 1 to 2 mm in size, and our targeted chemotherapeutic, which delivers potent doses of paclitaxel directly to the tumor.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

4041 Forest Park Ave.
Saint Louis, MO 63108
USA

Phone

(314) 633-1879

Website

www.kereos.com

Email Address

[email protected]

Overview

Kereos, a biotechnology company developing targeted imaging agents and therapeutics to improve the detection and treatment of cancer and cardiovascular disease,

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Executive Vice President

John Hefti

VP - Manufacturing

Kendall Killgore

Browse more venture capital transactions:

Prev: 9/20/2005: Mirapoint Software venture capital transaction
Next: 9/21/2005: Capella Photonics venture capital transaction

Share this article

About Our VC Transactions Data

We report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary